Media

PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA

Posted: May 16, 2023

PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health

Posted: May 01, 2023

PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin

Posted: Apr 25, 2023

PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA

Posted: Apr 20, 2023

PharmAla Biotech and Filament Health Announce Release of GMP MDMA Capsules

Posted: Apr 11, 2023

PharmAla Biotech named Exclusive MDMA Supply Partner to Awakn Life Sciences

Posted: Mar 01, 2023

PharmAla Biotech Completes Annual General Meeting

Posted: Feb 28, 2023

CEO Letter to Shareholders

Posted: Feb 28, 2023

Patent Application Published for PharmAla Biotech’s MDMA Analogs

Posted: Feb 23, 2023

PharmAla Biotech closes purchase order with Emyria Ltd., completes filing of “LaNeo” trademark in Australia

Posted: Feb 14, 2023

Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change

Posted: Feb 03, 2023

PharmAla Biotech granted an Export Permit for 300 grams of LaNeo™ MDMA

Posted: Jan 24, 2023

PharmAla Completes Pre-IND Meeting with FDA, to present at KCSA Virtual Investor Conference

Posted: Dec 13, 2022

Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement

Posted: Nov 16, 2022

PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA

Posted: Nov 02, 2022

PharmAla appoints Dr. Leah Mayo to Scientific Advisory Board

Posted: Oct 13, 2022

PharmAla Contracts with Clerkenwell to bring safer MDMA analogue to US, UK

Posted: Oct 11, 2022

PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply

Posted: Oct 06, 2022

PharmAla Biotech to supply University of California Clinical Trial with LaNeo™ MDMA

Posted: Oct 05, 2022

PharmAla Biotech to supply University of Sydney Clinical Trial with LaNeo™️ MDMA

Posted: Aug 31, 2022

PharmAla Biotech completes filing of patent application for 6 MDMA analogs

Posted: Aug 29, 2022

PharmAla Biotech to supply Major Australian Research Institute with LaNeo™ MDMA for Phase 3 Clinical Trial

Posted: Aug 22, 2022

PharmAla Biotech First Publicly Traded Company to Produce GMP MDMA

Posted: Aug 15, 2022

PharmAla Biotech Applauds Sen. Cory Booker and Sen. Rand Paul's Bill to Include MDMA in "Right-to-Try" Legislation

Posted: Aug 04, 2022

PharmAla Biotech appoints Kevin Roy to its Board of Directors

Posted: Jul 04, 2022

PharmAla Biotech Registers Trademark for MDMA

Posted: Jun 24, 2022

PharmAla Biotech Supports Decision to Decriminalize Possession of MDMA in British Columbia

Posted: Jun 02, 2022

Psychedelics Canada Announces The Launch Of The First National Trade Association For Legal Psychedelics Companies

Posted: May 27, 2022

PharmAla Biotech & SABI Mind Announce MDMA Supply Agreement

Posted: May 19, 2022

PharmAla Biotech Expands MDMA Distribution with CCrest Labs

Posted: May 10, 2022

PharmAla Biotech to supply Mind Medicine Australia with GMP MDMA for Clinical Trial

Posted: Apr 09, 2022

PharmAla Biotech adds David Purcell as Director of Sales

Posted: Mar 14, 2022

PharmAla Biotech contracts with InterVivo Solutions to validate novel MDMA analogs

Posted: Mar 07, 2022

Global Wellness Strategies Signs MDMA Supply Agreement with PharmAla Biotech

Posted: Feb 10, 2022

PharmAla Biotech initiates research at the University of Arkansas for Medical Sciences

Posted: Jan 17, 2022

PharmAla Biotech Announces Listing on the Canadian Securities Exchange

Posted: Jan 10, 2022